Dialysable nonspecific inhibitor of lymphocyte proliferation related to E-receptors (CD2)

P R Wunder1, F V da Fonseca, C G Musatti

  • 1Department of Immunology, Escola Paulista de Medicina, São Paulo, Brazil.

Insights

Normal human serum dialysate (NHSD) inhibits lymphocyte proliferation by affecting later stages of the cell cycle. This suppressive factor is linked to the sheep erythrocyte receptor (T11 or CD2) on T cells.

Area of Science:

  • Immunology
  • Cell Biology

Background:

  • Soluble factors in human serum can significantly impact lymphocyte function.
  • Previous studies indicated that normal human serum dialysate (NHSD) inhibits lymphocyte proliferation.
  • This inhibition was linked to a factor associated with the T cell receptor for sheep erythrocytes (E).

Purpose of the Study:

  • To determine the specific phase of the proliferative response affected by NHSD.
  • To further confirm the association of the inhibitory factor with E-receptors.
  • To investigate the mechanism of NHSD-induced immunosuppression.

Main Methods:

  • Time-course experiments adding NHSD at various times during lymphocyte cultures.
  • Affinity chromatography using a sepharose column sensitized with anti-E-receptor serum.
  • Assessing proliferation in response to phytohemagglutinin (PHA) and interleukin-2 (IL2).

Main Results:

  • NHSD inhibited lymphocyte proliferation even when added 18-24 hours after PHA stimulation.
  • The suppressive effect was inversely proportional to the time of NHSD addition in mixed lymphocyte cultures.
  • NHSD also inhibited IL2-mediated proliferation of lymphoblasts, indicating an effect on IL2-receptor expressing cells.
  • Inhibitory effects were abolished by absorption with E or passage through the anti-E-receptor affinity column.

Conclusions:

  • NHSD contains a dialyzable factor that inhibits lymphocyte proliferation during later phases of the cell cycle.
  • This factor is closely related to the T cell E-receptor (T11 or CD2).
  • The findings elucidate a novel mechanism of serum-mediated immune regulation.